KSI.V - kneat.com, inc.

TSXV - TSXV Delayed Price. Currency in CAD
1.4900
+0.0300 (+2.05%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close1.4600
Open1.4800
Bid1.4900 x 0
Ask1.5000 x 0
Day's Range1.4700 - 1.5000
52 Week Range0.8600 - 1.6500
Volume124,817
Avg. Volume26,266
Market Cap90.889M
Beta (3Y Monthly)0.07
PE Ratio (TTM)N/A
EPS (TTM)-0.1150
Earnings DateAug 27, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Could kneat.com, inc.'s (CVE:KSI) Investor Composition Influence The Stock Price?
    Simply Wall St.

    Could kneat.com, inc.'s (CVE:KSI) Investor Composition Influence The Stock Price?

    The big shareholder groups in kneat.com, inc. (CVE:KSI) have power over the company. Insiders often own a large chunk...

  • Kneat Appoints New Chief Financial Officer
    CNW Group

    Kneat Appoints New Chief Financial Officer

    LIMERICK, Ireland , Sept. 20, 2019 /CNW/ - kneat.com, inc. (KSI.V) ("Kneat" or the "Company") today announced that it has appointed Mr. Hugh Kavanagh as its Chief Financial Officer effective September 23, 2019 following the resignation of Ms. Sarah Oliver who will assist in the transition. Mr. Kavanagh has held senior positions at several multi-national companies in the software and life sciences industries, most recently as Chief Financial Officer of Mainstay Medical during which time he completed an initial public offering and several rounds of funding. "The Board and I are pleased to welcome Hugh to Kneat's executive management team. Kneat will benefit from Hugh's broad financial, operational and capital markets experience as we continue to grow our operations globally", said Eddie Ryan , Chief Executive Officer of Kneat.

  • Big Pharma selects Kneat's Commissioning, Qualification and Validation platform
    CNW Group

    Big Pharma selects Kneat's Commissioning, Qualification and Validation platform

    LIMERICK, Ireland , Sept. 17, 2019 /CNW/ - kneat.com, inc. (KSI.V) ("Kneat") is pleased to announce that it signed a three-year contract with one of the worlds largest pharmaceutical companies to enable digital transformation for its many validation work processes.   This master service agreement allows the customer and its affiliates to expand Kneat Gx across its 100+ global manufacturing sites and represents a significant opportunity for growth and expansion of Kneat's software. Kneat continues to expand its customer pipeline and will report on further developments as they occur.

  • Kneat Reports Second Quarter Results
    CNW Group

    Kneat Reports Second Quarter Results

    LIMERICK, Ireland , Aug. 27, 2019 /CNW/ - kneat.com, inc. (KSI.V) ("Kneat") today announced its financial results for the quarter ended June 30 , 2019. All dollar amounts are presented in Canadian dollars unless otherwise stated. During the quarter, two customers deployed our SaaS platform. Year to date, four customers have successfully gone live on our SaaS platform and two customers have started to scale their use of our on-premise solution.

  • How Does kneat.com, inc. (CVE:KSI) Affect Your Portfolio Volatility?
    Simply Wall St.

    How Does kneat.com, inc. (CVE:KSI) Affect Your Portfolio Volatility?

    If you own shares in kneat.com, inc. (CVE:KSI) then it's worth thinking about how it contributes to the volatility of...

  • Does kneat.com, inc.'s (CVE:KSI) CEO Pay Matter?
    Simply Wall St.

    Does kneat.com, inc.'s (CVE:KSI) CEO Pay Matter?

    The CEO of kneat.com, inc. (CVE:KSI) is Eddie Ryan. This analysis aims first to contrast CEO compensation with other...

  • Global CDMO partners with Kneat to Digitize their Validation work Processes
    CNW Group

    Global CDMO partners with Kneat to Digitize their Validation work Processes

    LIMERICK, Ireland , July 22, 2019 /CNW/ - kneat.com, inc. (KSI.V) ("Kneat") is pleased to announce that a global contract development and manufacturing organization ("CDMO") has selected Kneat's platform to digitize their commissioning, qualification and validation work processes. This customer contracted with Kneat for on-premise perpetual licenses on July 12, 2019 and is expected to go live at a European site on multiple processes by the end of the year.  Expansion to all global sites is expected in the future. "We're happy to be fulfilling such a key role within this customer's highly regulated GMP manufacturing facility," said Eddie Ryan , Chief Executive Officer of Kneat.

  • Pioneering Biotech Selects Kneat for its Validation Life Cycle Management
    CNW Group

    Pioneering Biotech Selects Kneat for its Validation Life Cycle Management

    LIMERICK, Ireland , June 17, 2019 /CNW/ - kneat.com, inc. (KSI.V) ("Kneat") is pleased to announce that a leading company in the field of messenger RNA ("mRNA") has selected Kneat's software as a service ("SaaS") platform for its validation lifecycle management work processes.  Initially this customer will configure its computer system validation ("CSV") work process on the platform and expand to other validation processes in the future. Kneat's team will begin deployment at the customer's United States headquarters in the coming weeks with an expected go-live date for CSV in the fourth quarter of 2019.  In line with Kneat's typical contracts, this subscription agreement is for three years starting on June 11, 2019 .

  • Kneat to provide Corporate Update via webcast on June 19, 2019
    CNW Group

    Kneat to provide Corporate Update via webcast on June 19, 2019

    Kneat to provide Corporate Update via webcast on June 19, 2019

  • Kneat Reports First Quarter Results
    CNW Group

    Kneat Reports First Quarter Results

    HALIFAX , May 28, 2019 /CNW/ - kneat.com, inc. (KSI.V) ("Kneat") today announced its financial results for the quarter ended March 31 , 2019.  All dollar amounts are presented in Canadian dollars unless otherwise stated. Kneat announced a new biotechnology customer win during the quarter to add to the seven multinational customers announced in 2018. This customer has over 20,000 employees globally across four continents and will use the Kneat Gx platform ("Kneat Gx") to take their facilities, utilities and equipment commissioning and qualification processes fully digital.

  • Kneat Appoints SaaS Industry Veteran, Rory Cameron, as New Board Member
    CNW Group

    Kneat Appoints SaaS Industry Veteran, Rory Cameron, as New Board Member

    HALIFAX , May 1, 2019 /CNW/ - kneat.com, inc. (KSI.V) ("Kneat") is pleased to announce that Mr. Rory Cameron has been appointed to its Board of Directors.  Mr. Cameron has over 15 years of experience in the software industry and an extensive background in mergers, acquisitions and go-to-market operations within global cloud companies.  Mr. Cameron recently joined Medallia as Executive Vice President, Corporate Development where he is focusing on accelerating Medallia's growth through new technology partnerships and acquisitions.  Prior to joining Medallia, Mr. Cameron was Executive Vice President of Corporate Development at CallidusCloud until its sale to SAP.

  • Kneat Reports Fourth Quarter Results
    CNW Group

    Kneat Reports Fourth Quarter Results

    HALIFAX , April 24, 2019 /CNW/ - kneat.com, inc. (KSI.V) ("Kneat") today announced its financial results for the quarter and year ended December 31 , 2018.  All dollar amounts are presented in Canadian dollars unless otherwise stated. Revenue of $465,205 was recognized during the fourth quarter.  Total revenue for the 2018 financial year was $1,307,295 which was an increase of 210% over the previous year.  Revenue in all categories increased quarter over quarter and year over year. During the fourth quarter Kneat announced two new software as a service ("SaaS") customer wins within the life sciences supply chain.  Both customers have chosen Kneat to implement paperless computer systems validation ("CSV") processes.  This is an important market for Kneat as data integrity and compliance regulations govern the entire supply chain to the life sciences industry.

  • Kneat to Present at Bloom Burton & Co. Healthcare Investor Conference
    CNW Group

    Kneat to Present at Bloom Burton & Co. Healthcare Investor Conference

    Kneat to Present at Bloom Burton & Co. Healthcare Investor Conference

  • Kneat Signs Global Biotechnology Leader
    CNW Group

    Kneat Signs Global Biotechnology Leader

    HALIFAX , March 11, 2019 /CNW/ - kneat.com, inc. (KSI.V) ("Kneat") is pleased to announce that an international leader in biotechnology has chosen Kneat's software platform to facilitate its transition to paperless validation processes.  With over 20,000 employees globally and manufacturing facilities in four continents, this company develops innovative therapies for patients around the world.  Kneat's platform will initially be launched for facilities, utilities and equipment commissioning and qualification ("C&Q") at a manufacturing plant in the United States . "We look forward to working closely with this customer to convert their current paper C&Q process to an end-to-end digital process," said Eddie Ryan , Chief Executive Officer of Kneat. Kneat continues to expand its customer pipeline and will report on further developments as they occur.

  • Kneat Announces Grant of Stock Options
    CNW Group

    Kneat Announces Grant of Stock Options

    Kneat Announces Grant of Stock Options

  • Kneat and HCL Technologies Partner to Deliver Digital Validation Solutions to Life Sciences
    CNW Group

    Kneat and HCL Technologies Partner to Deliver Digital Validation Solutions to Life Sciences

    This partnership represents a key element in Kneat's strategy to deliver greater value to its current customers and to grow and scale to new customers.  Kneat and HCL will work together on projects to provide and implement next generation digital solutions for facilities, equipment and computer systems validation processes using Kneat's paperless software platform and HCL's experience delivering innovative digital solutions to the life sciences industry.

  • /C O R R E C T I O N from Source -- kneat.com, inc./
    CNW Group

    /C O R R E C T I O N from Source -- kneat.com, inc./

    In the news release, Kneat Announces Closing of $6,339,375 Public Equity Financing and Concurrent $2,178,159 Non-Brokered Private Placement Equity Financing, issued 20-Feb-2019 by kneat.com, inc. over CNW, we are advised by the company that a new paragraph was added to the release, the third one below. HALIFAX , Feb. 20, 2019 /CNW/ - kneat.com, inc. (KSI.V) ("Kneat" or the "Company") is pleased to announce that it has closed its previously announced short form prospectus offering, including the full exercise of the over-allotment option. As such, a total of 6,037,500 common shares of the Company were sold at a price of $1.05 per common share (the "Issue Price") for aggregate gross proceeds of $6,339,375 (the "Offering").

  • Recently Signed Customer Scales Kneat's platform to Second Site
    CNW Group

    Recently Signed Customer Scales Kneat's platform to Second Site

    "In 2018 we signed seven multinational customers in the life sciences industry and three went live in the second half of 2018 with initial deployments.  All three are now expanding their use of the platform.  The other four customers are now in the process of their initial deployment and we look forward to working with them as they go-live," said Eddie Ryan , Chief Executive Officer of Kneat. Kneat continues to expand its customer pipeline and will report on further developments as they occur. Kneat develops and markets the next generation Kneat Gx software platform.  Multiple business processes can be configured on the platform from equipment to computer system validation, through to quality document management.  Kneat's software allows users to author, review, approve, execute testing online, manage any exceptions and post approve final deliverables in a controlled FDA 21 CFR Part 11/ Eudralex Annex 11 compliant platform.  Macro and micro report dashboards enable powerful oversight into all systems, projects and processes world wide.  Customer case studies are reporting productivity improvements in excess of 100% and a higher data integrity and compliance standard.  For more information visit www.kneat.com.

  • Kneat announces customer expansion at flagship US site and provides financing update
    CNW Group

    Kneat announces customer expansion at flagship US site and provides financing update

    HALIFAX , Feb. 13, 2019 /CNW/ - kneat.com, inc. (KSI.V) ("Kneat") is pleased to announce that a leading laboratory services customer is expanding its user base on the Kneat platform within its flagship site in the United States.  This expansion will double the customer's license numbers.  This customer first implemented the Kneat platform in December 2018 with the ultimate goal of creating a standardized, compliant and automated equipment and instrument validation process globally.  The new licenses will be rolled out immediately. "We are pleased to see our customer increase the number of users within its flagship site", said Eddie Ryan , Chief Executive Officer of Kneat. Kneat continues to expand its customer pipeline and will report on further developments as they occur.

  • CNW Group

    IIROC Trading Resumption - KSI

    IIROC Trading Resumption - KSI

  • CNW Group

    Kneat Announces Overnight Marketed Equity Financing

    HALIFAX , Feb 7, 2019 /CNW/ - kneat.com, inc. (KSI.V) ("Kneat") is pleased to announce that, in connection with its previously announced overnight marketed offering, it has entered into an underwriting agreement with a syndicate of underwriters led by Cormark Securities Inc., and including Echelon Wealth Partners Inc. and Mackie Research Capital Corporation (collectively, the "Underwriters"), to sell 5,250,000 Common Shares of the Company ("Securities") at a price of $1.05 per Security for aggregate gross proceeds of $5,512 ,500 the "Offering"). Kneat will shortly file an amended and restated preliminary short form prospectus with the securities commissions in all of the provinces of Canada , other than Québec, to reflect the terms of the Offering. Kneat has granted the Underwriters an option (the "Over-Allotment Option") to purchase up to an additional 787,500 of Securities on the same terms as the Offering, exercisable at any time up to 30 days following the closing of the Offering, for market stabilization purposes and to cover over-allotments, if any.

  • CNW Group

    IIROC Trading Halt - KSI

    IIROC Trading Halt - KSI

  • What You Must Know About kneat.com, inc.’s (CVE:KSI) Financial Strength
    Simply Wall St.

    What You Must Know About kneat.com, inc.’s (CVE:KSI) Financial Strength

    kneat.com, inc. (CVE:KSI) is a small-cap stock with a market capitalization of CA$63m. While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, they end Read More...

  • CNW Group

    Kneat Expands Within Life Sciences Supply Chain

    HALIFAX , Dec. 20, 2018 /CNW/ - kneat.com, inc. (KSI.V) ("Kneat") is pleased to announce that it has signed a master service agreement with a new customer in the life sciences supply chain. This multi-national customer provides sample lifecycle and logistics management, infrastructure and consumables, including cold storage of biological assets, to global pharmaceutical companies and will now use Kneat's software to automate and simplify their validation processes in the delivery of these services. "Kneat's momentum within the life sciences market continues as industry leaders in the supply chain select our software to drive efficiencies, support data integrity and maintain compliant processes," said Eddie Ryan , Chief Executive Officer of Kneat.